Verizon Communications Inc vs Zimmer Biomet Holdings Inc — how do they compare? Verizon Communications Inc trades at $43.74 (market cap $181.64B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Verizon Communications Inc is far larger — about 10.5× Zimmer Biomet Holdings Inc's market cap, and Verizon Communications Inc pays the higher dividend (6.51%). Which is the better fit depends on your goals.
| VZ | ZBH | |
|---|---|---|
Market Cap | $181.64B | $17.36B |
Volume | 22,584,735 | — |
Sector | Media | Health |
52-Week High | $51.38 | $107.71 |
52-Week Low | $38.40 | $79.58 |
Enterprise Value | $369.14B | $24.40B |
Dividend Yield | 6.51% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
Verizon (VZ) trades at $43.78, up 0.44% today, with a bearish technical signal but strong fundamentals including a P/E of 10.61 and consistent earnings beats. Recent news highlights a restructuring involving 3,000 job cuts and the sale of 274 stores to franchisees, aimed at boosting efficiency ahead of Q2 2026 earnings. Cash flow improved in 2025 with net cash flow of $14.9 billion, supporting its 6.5% dividend yield.
Outlook: Attractive for income investors due to stable cash flows and high dividend, but faces risks from 5G competition and margin pressure. Analyst consensus price target is $47.83, suggesting upside potential if execution improves. Key risks include debt levels and industry discounts threatening profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →